Your browser doesn't support javascript.
Шоу: 20 | 50 | 100
Результаты 1 - 3 de 3
Фильтр
1.
J Minim Access Surg ; 17(4): 542-547, 2021.
Статья в английский | MEDLINE | ID: covidwho-1431013

Реферат

BACKGROUND: Although safe practice guidelines were issued by the Obesity and Metabolic Surgery Society of India (OSSI) in the end of May 2020, surgeons have been in a dilemma about risk of subjecting patients to hospitalisation and bariatric surgery. This survey was conducted with the objective to evaluate the risk of coronavirus disease-19 (COVID-19) infection in peri- and post-operative period after bariatric and metabolic surgery (BMS). METHODS: A survey with OSSI members was conducted from 20 July 2020 to 31 August 2020 in accordance with EQUATOR guidelines. Google Form was circulated to all surgeon members through E-mail and WhatsAppTM. In the second phase, clinical details were captured from surgeons who reported positive cases. RESULTS: One thousand three hundred and seven BMS were reported from 1 January 2020 to 15 July 2020. Seventy-eight per cent were performed prior to 31 March 2020 and 276 were performed after 1 April 2020. Of these, 13 (0.99%) patients were reported positive for COVID-19 in the post-operative period. All suffered from a mild disease and there was no mortality. Eighty-seven positive cases were reported from patients who underwent BMS prior to 31 December 2019. Of these, 82.7% of patients had mild disease, 13.7% of patients had moderate symptoms and four patients succumbed to COVID-19. CONCLUSION: BMS may be considered as a safe treatment option for patients suffering from clinically severe obesity during the COVID-19 pandemic. Due care must be taken to protect patients and healthcare workers and all procedures must be conducted in line with the safe practice guidelines.

2.
Crit Rev Ther Drug Carrier Syst ; 38(3): 75-115, 2021.
Статья в английский | MEDLINE | ID: covidwho-1236628

Реферат

The outbreak of novel coronavirus (nCoV) or severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in December 2019 in Wuhan, China, has posed an international public health emergency worldwide and forced people to be confined in their homes. This virus is of high-risk category and is declared a pandemic by the World Health Organization (WHO). The worldwide researchers and various health professionals are working together to determine the best way to stop its spread or halt this virus's spread and circumvent this pandemic condition threatening millions of human lives. The absence of definitive treatment is possible to explore to reduce virus infection and enhance patient recovery. Along with off-label medicines, plasma therapy, vaccines, the researchers exploit the various plants/herbs and their constituents to effectively treat nCoV infection. The present study aimed to present brief and most informative salient features of the numerous facts regarding the SARS-CoV-2, including the structure, genomic sequence, recent mutation, targeting possibility, and various hurdles in research progress, and off-labeled drugs, convalescent plasma therapy, vaccine and plants/herbs for the treatment of coronavirus disease-2019 (COVID-19). Results showed that off-labeled drugs such as hydroxychloroquine, dexamethasone, tocilizumab, antiviral drug (remdesivir, favipiravir), etc., give positive results and approved for use or approved for restricted use in some countries like India. Future research should focus on these possibilities that may allow the development of an effective treatment for COVID-19.


Тема - темы
Antiviral Agents/pharmacology , COVID-19 Drug Treatment , COVID-19 Vaccines/administration & dosage , Plant Extracts/pharmacology , SARS-CoV-2/drug effects , Angiotensin-Converting Enzyme 2/antagonists & inhibitors , Angiotensin-Converting Enzyme 2/metabolism , Antiviral Agents/therapeutic use , COVID-19/epidemiology , COVID-19/immunology , COVID-19/virology , Clinical Trials as Topic , Drug Therapy, Combination/methods , Humans , Molecular Targeted Therapy/methods , Mutation , Off-Label Use , Pandemics/prevention & control , Plant Extracts/therapeutic use , SARS-CoV-2/genetics , SARS-CoV-2/immunology , SARS-CoV-2/metabolism , Treatment Outcome , Viral Structural Proteins/antagonists & inhibitors , Viral Structural Proteins/genetics , Viral Structural Proteins/metabolism
3.
Obes Surg ; 30(12): 5101-5107, 2020 12.
Статья в английский | MEDLINE | ID: covidwho-724069

Реферат

Bariatric and metabolic surgery (BMS), the only effective option for patients with obesity with or without comorbidities, has been stopped temporarily due to the ongoing novel corona virus disease (COVID-19) pandemic. However, there has been a recent change in the governmental strategy of dealing with this virus from 'Stay at Home' to 'Stay Alert' in many countries including India. A host of health services including elective surgeries are being resumed. In view of the possibility of resumption of BMS in near future, Obesity and Metabolic Surgery Society of India (OSSI) constituted a committee of experienced surgeons to give recommendations about the requirements as well as precautions to be taken to restart BMS with emphasis on safe delivery and high-quality care.


Тема - темы
Bariatric Surgery/standards , COVID-19/epidemiology , Pandemics , Societies, Medical , COVID-19/prevention & control , COVID-19/transmission , COVID-19 Testing , Diagnostic Imaging , Humans , India/epidemiology , Infection Control , Infectious Disease Transmission, Patient-to-Professional/prevention & control , Informed Consent , Operating Rooms/organization & administration , Patient Discharge , Patient Selection , Personal Protective Equipment , Postoperative Care , Preoperative Care
Критерии поиска